menu
    • menu
    [{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Aradigm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aradigm \/ Grifols International","highestDevelopmentStatusID":"10","companyTruncated":"Aradigm \/ Grifols International"},{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Aradigm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aradigm \/ Grifols International","highestDevelopmentStatusID":"10","companyTruncated":"Aradigm \/ Grifols International"},{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aradigm","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Aradigm \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Aradigm \/ Grifols International"}]

    Find Clinical Drug Pipeline Developments & Deals by Aradigm

    Menu

    Aradigm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aradigm

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aradigm

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciprofloxacin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Grifols International

                            Deal Size : $6.2 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Aradigm Announces Entering into an Asset Purchase Agreement with Grifols, S.A.

                            Details : Grifols, S.A.will acquire the Company’s assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : $3.2 million

                            February 21, 2020

                            Lead Product(s) : Ciprofloxacin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Grifols International

                            Deal Size : $6.2 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aradigm

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aradigm

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciprofloxacin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Grifols International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

                            Details : Ciprofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bronchiectasis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 04, 2014

                            Lead Product(s) : Ciprofloxacin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Grifols International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aradigm

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aradigm

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciprofloxacin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Grifols International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

                            Details : Ciprofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bronchiectasis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 23, 2012

                            Lead Product(s) : Ciprofloxacin

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Grifols International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth